We use our own and third-party cookies to optimize your experience on this site, including to maintain user sessions. Without these cookies our site will not function well. If you continue browsing our site we take that to mean that you understand and accept how we use the cookies. If you wish to decline our cookies we will redirect you to Google.
Already have an account? Sign in.

 Remember Me | Forgot Your Password?

EC Approves GSK's Weight-Loss Drug for OTC Sales

April 20, 2009: 11:49 AM EST
GlaxoSmithKline’s weight-loss drug alli™ is now available over the counter throughout Europe to people with a BMI of 28 or more. It is the first approval for a non-prescription weight loss product in Europe. Clinical trials have shown that alli, used as part of a reduced-calorie, low-fat diet, can help people to lose 50 percent more weight than the diet alone. The drug is being distributed only through pharmacies, and is backed by an online support program. The recommended dose is 60mg three times a day. alli has been available in the US for some time.
"GlaxoSmithKline launches alli® (orlistat 60 mg)", GSK, April 20, 2009, © GlaxoSmithKline plc
Diet Insights
Weight Loss Programs
Other Diets
Diet Research & Advice
Market News
Policy & Regulation
North America
United States of America
United Kingdom
Companies, Organizations
Legal, Legislation, Regulation, Policy
Press Release
Products & Brands
Developed by Yuri Ingultsov Software Lab.